Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this study is to compare the confirmed objective response rate (ORR) by Week 19 following treatment with bevacizumab-Pfizer in combination with paclitaxel and carboplatin to bevacizumab-EU plus paclitaxel and carboplatin in patients who have not received previous treatment for advanced non-squamous non-small cell lung cancer (NSCLC).
Inclusion criteria
- Advanced Non-Squamous Non Small Cell Lung cancer